Surio Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Series B

  • Investors
  • 14

Surio Therapeutics General Information

Description

Manufacturer of biotechnology therapeutics intended to develop innovative treatments for metabolic, cardiovascular, and related diseases. The company offers peptide drug discovery, biologic engineering, and translational research capabilities, enabling pharmaceutical companies and healthcare providers to advance targeted therapeutics and improve treatment outcomes.

Contact Information

Formerly Known As
Suzhou Ruiao Biotechnology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4th Floor, Building 3, Westlake University Science Park
  • Number 1 Yunmeng Road, Zhuantang Street, Xihu District
  • Hangzhou, Zhejiang 310024
  • China
+86 182
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 4th Floor, Building 3, Westlake University Science Park
  • Number 1 Yunmeng Road, Zhuantang Street, Xihu District
  • Hangzhou, Zhejiang 310024
  • China
+86 182

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Surio Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series B) 02-Nov-2026 Completed Generating Revenue
5. Later Stage VC (Series A) 28-May-2026 Completed Generating Revenue
4. Secondary Transaction - Private 14-Oct-2025 Completed Generating Revenue
3. Early Stage VC 10-Aug-2023 Completed Generating Revenue
2. Early Stage VC 19-Nov-2021 $843K Completed Generating Revenue
1. Seed Round 24-Sep-2019 $843K $843K Completed Startup
To view Surio Therapeutics’s complete valuation and funding history, request access »

Surio Therapeutics Patents

Surio Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025036407-A1 Aldh-activable funtionalized monosaccarides, pharmaceutical compositions, and diagnostic and therapeutic applications Inactive 15-Aug-2023
AU-2024288440-A1 Functionalized auristatins, pharmaceutical compositions, and therapeutic applications Pending 10-Jul-2023
EP-4743118-A1 Functionalized auristatins, pharmaceutical compositions, and therapeutic applications Pending 10-Jul-2023
WO-2025011557-A1 Functionalized auristatins, pharmaceutical compositions, and therapeutic applications Inactive 10-Jul-2023
US-20260200964-A1 Monosaccarides, pharmaceutical compositions, and diagnostic and therapeutic applications Pending 08-Dec-2022 C07H15/26
To view Surio Therapeutics’s complete patent history, request access »

Surio Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Surio Therapeutics Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Capital Science and Technology Development Group Venture Capital Minority
Wuhan Optics Valley Industrial Investment Growth/Expansion Minority
Highlight Capital Venture Capital Minority
Shanghai Songqing Private Equity Fund Management Growth/Expansion Minority
Hangzhou Dongfang Jiafu Asset Management Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

Surio Therapeutics FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process